Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at ValuEngine

ValuEngine upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a buy rating to a strong-buy rating in a research note issued to investors on Monday, ValuEngine reports.

TNDM has been the topic of a number of other research reports. UBS Group increased their target price on Tandem Diabetes Care from $53.00 to $66.00 and gave the company a neutral rating in a report on Tuesday, April 30th. Leerink Swann began coverage on Tandem Diabetes Care in a report on Monday, May 13th. They issued an outperform rating and a $83.00 target price on the stock. Lake Street Capital reissued a buy rating on shares of Tandem Diabetes Care in a report on Monday, June 17th. Stifel Nicolaus increased their target price on Tandem Diabetes Care from $58.00 to $70.00 and gave the company a hold rating in a report on Wednesday, May 1st. Finally, Oppenheimer increased their target price on Tandem Diabetes Care from $80.00 to $84.00 in a report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Tandem Diabetes Care currently has an average rating of Buy and a consensus price target of $68.38.

TNDM stock opened at $59.77 on Monday. Tandem Diabetes Care has a fifty-two week low of $26.40 and a fifty-two week high of $74.81. The firm has a 50-day moving average price of $63.72. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.21 and a current ratio of 2.53. The company has a market capitalization of $3.53 billion, a P/E ratio of -23.44 and a beta of 0.33.



Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, August 1st. The medical device company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.20. Tandem Diabetes Care had a negative return on equity of 19.31% and a negative net margin of 19.55%. The company had revenue of $93.26 million for the quarter, compared to the consensus estimate of $69.95 million. During the same quarter in the prior year, the company earned ($0.33) earnings per share. Tandem Diabetes Care’s revenue was up 173.2% on a year-over-year basis. On average, sell-side analysts anticipate that Tandem Diabetes Care will post -0.65 EPS for the current year.

In other news, Director Douglas A. Roeder sold 35,688 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $70.07, for a total value of $2,500,658.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP David B. Berger sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $67.76, for a total value of $135,520.00. Following the completion of the transaction, the executive vice president now directly owns 5,311 shares in the company, valued at approximately $359,873.36. The disclosure for this sale can be found here. Insiders sold 108,954 shares of company stock worth $7,398,525 in the last ninety days. Corporate insiders own 6.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in TNDM. Nisa Investment Advisors LLC grew its position in shares of Tandem Diabetes Care by 53.3% during the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after purchasing an additional 160 shares in the last quarter. Bremer Bank National Association purchased a new position in Tandem Diabetes Care during the 1st quarter valued at approximately $31,000. TRUE Private Wealth Advisors purchased a new position in Tandem Diabetes Care during the 2nd quarter valued at approximately $33,000. James Investment Research Inc. grew its holdings in Tandem Diabetes Care by 15.9% during the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after buying an additional 180 shares in the last quarter. Finally, Stephens Inc. AR purchased a new position in Tandem Diabetes Care during the 2nd quarter valued at approximately $113,000. Hedge funds and other institutional investors own 79.75% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: How do CD ladders protect against rising interest rates?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.